| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0264-410X(01)00020-2 |
| P698 | PubMed publication ID | 11312014 |
| P2093 | author name string | Sun W | |
| King A | |||
| Innis BL | |||
| Saluzzo JF | |||
| Vaughn DW | |||
| Zahradnik JM | |||
| Hoke CH Jr | |||
| Putnak JR | |||
| Gilson K | |||
| Christ-Schmidt H | |||
| Kanesa-thasan N | |||
| Kim-Ahn G | |||
| Raengsakulsrach B | |||
| Van Albert S | |||
| P2860 | cites work | Dengue: the risk to developed and developing countries | Q29619739 |
| Dengue and dengue haemorrhagic fever | Q29620093 | ||
| Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production | Q34566234 | ||
| Live attenuated tetravalent dengue vaccine | Q40621161 | ||
| Rapid diagnosis of dengue viremia by reverse transcriptase-polymerase chain reaction using 3'-noncoding region universal primers | Q40652656 | ||
| Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers | Q40671401 | ||
| A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans | Q40693060 | ||
| Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. | Q40759585 | ||
| Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status | Q40831942 | ||
| In vitro homotypic and heterotypic interference by defective interfering particles of West Nile virus | Q41657407 | ||
| Study of bivalent dengue vaccine in volunteers | Q42989607 | ||
| Randomised trial of alternative formulations of oral poliovaccine in Brazil | Q57113048 | ||
| P433 | issue | 23-24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Dengue virus | Q476209 |
| attenuated vaccine | Q1810913 | ||
| P304 | page(s) | 3179-3188 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers | |
| P478 | volume | 19 |
| Q41930017 | A lethal model of disseminated dengue virus type 1 infection in AG129 mice |
| Q37812291 | A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies |
| Q37492736 | A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys |
| Q33988937 | A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial |
| Q51336360 | A systematic approach to the development of a safe live attenuated Zika vaccine. |
| Q40553373 | A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. |
| Q27478104 | An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes |
| Q39132688 | An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity |
| Q40081626 | Antibody Prophylaxis Against Dengue Virus 2 Infection in Non-Human Primates |
| Q92650511 | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003 |
| Q40457185 | Attenuating characteristics of DEN-2 PDK53 in flavivirus-naïve peripheral blood mononuclear cells. |
| Q33402211 | Changes in hematological and serum biochemical parameters in common marmosets (Callithrix jacchus) after inoculation with dengue virus |
| Q27477541 | Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus Macaques |
| Q27469872 | Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice |
| Q27469831 | Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus |
| Q28237906 | Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis |
| Q41082678 | Combined infectious bronchitis virus Arkansas and Massachusetts serotype vaccination suppresses replication of Arkansas vaccine virus |
| Q49920855 | Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate |
| Q39223992 | Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus. |
| Q27469921 | Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine |
| Q27485759 | Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development |
| Q37039194 | Dengue Vaccine: The Current Status |
| Q37778918 | Dengue conundrums |
| Q35625026 | Dengue epidemiology: virus epidemiology, ecology, and emergence |
| Q40256702 | Dengue vaccine efficacy trial: does interference cause failure? |
| Q47562022 | Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies |
| Q35964754 | Dengue vaccine: priorities and progress |
| Q37194772 | Dengue vaccines for travelers |
| Q34109652 | Dengue vaccines: state of the art. |
| Q27477895 | Dengue viral infections |
| Q27485404 | Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4 |
| Q24609884 | Dengue: defining protective versus pathologic immunity |
| Q38201151 | Developing a dengue vaccine: progress and future challenges |
| Q35206695 | Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine |
| Q34202440 | Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever |
| Q24805060 | Development of Dengue virus type 2 replicons capable of prolonged expression in host cells |
| Q24797123 | Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV |
| Q92624604 | Dissecting the heterogeneity of DENV vaccine-elicited cellular immunity using single-cell RNA sequencing and metabolic profiling |
| Q35624552 | Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2 |
| Q42982539 | Editorial: the challenge of dengue vaccine development and introduction |
| Q40447644 | Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques. |
| Q35031833 | Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques |
| Q41922147 | Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence |
| Q35625041 | Empirically derived live-attenuated vaccines against dengue and Japanese encephalitis |
| Q40564204 | Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus |
| Q38916168 | Fever after a stay in the tropics. Part 2: Common imported tropical diseases |
| Q40541587 | Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus |
| Q40529413 | Identification of the homotypic interaction domain of the core protein of dengue virus type 2. |
| Q37901360 | Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms |
| Q40302299 | Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice |
| Q37137235 | Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice |
| Q36922684 | Immunologic hypo- or non-responder in natural dengue virus infection |
| Q40597033 | Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine |
| Q33961878 | Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines. |
| Q40474022 | Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. |
| Q40510477 | Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein |
| Q40528042 | Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity |
| Q21144539 | Japanese encephalitis-a pathological and clinical perspective |
| Q38618056 | Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates? |
| Q40418273 | Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys |
| Q24289053 | Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes |
| Q91725883 | Mimicking immune signatures of flavivirus infection with targeted adjuvants improves dengue subunit vaccine immunogenicity |
| Q66679750 | Molecular Simulations Reveal the Role of Antibody Fine Specificity and Viral Maturation State on Antibody-Dependent Enhancement of Infection in Dengue Virus |
| Q36906525 | Molecular determinants of plaque size as an indicator of dengue virus attenuation |
| Q38646923 | New insights into the immunopathology and control of dengue virus infection |
| Q35491639 | Next-generation dengue vaccines: novel strategies currently under development |
| Q35269464 | Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines |
| Q27472938 | Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes |
| Q24813811 | Peptide inhibitors of dengue virus and West Nile virus infectivity |
| Q77597822 | Pharmacoepidemiology and drug safety |
| Q27490989 | Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers |
| Q27487377 | Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity |
| Q33194696 | Policymakers’ views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries |
| Q27485489 | Primary and Secondary Infections of Macaca fascicularis Monkeys with Asian and American Genotypes of Dengue Virus 2 |
| Q35009119 | Progress towards a dengue vaccine |
| Q29619608 | Prospects for a dengue virus vaccine |
| Q39190598 | Protective efficacy of a single immunization with capripoxvirus-vectored recombinant peste des petits ruminants vaccines in presence of pre-existing immunity |
| Q40302309 | Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. |
| Q40378149 | Recent progress on sanofi pasteur's dengue vaccine candidate |
| Q27469474 | Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys |
| Q42991651 | Recombination and flavivirus vaccines: a commentary |
| Q27487570 | Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2 |
| Q36024479 | Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial |
| Q37423499 | Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates |
| Q36288109 | Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study |
| Q40235135 | Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. |
| Q37330751 | Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development |
| Q35625007 | Serodiagnosis of flaviviral infections and vaccinations in humans |
| Q39097395 | Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus |
| Q36118259 | Targeted mutagenesis as a rational approach to dengue virus vaccine development |
| Q33222362 | Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen |
| Q63246530 | The Conserved Molecular Determinants of Virulence in Dengue Virus |
| Q37350360 | Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses |
| Q35143285 | Traditional and novel approaches to flavivirus vaccines |
| Q42990713 | Updates on clinical pharmacology of dengue |
| Q37184768 | Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles |
| Q27485491 | Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections |
| Q24805308 | Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2 |
| Q27478162 | Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1 |
| Q35172628 | Vaccines for the prevention of neglected diseases--dengue fever |
| Q42984516 | Viral vaccine meeting held in Barcelona, October 25-28, 2003. |
| Q40245518 | Will people change their vector-control practices in the presence of an imperfect dengue vaccine? |
Search more.